FDA grants priority review for Daklinza (daclatasvir) sNDAs
Bristol-Myers announced the FDA has accepted for filing and review three sNDAs for Daklinza (daclatasvir), an NS5A replication complex inhibitor, for use with sofosbuvir with or without ribavirin. The applications are for patients with HCV coinfected with HIV-1, patients with advanced cirrhosis. October 06, 2015